Molecular Partners Yönetim

Yönetim kriter kontrolleri 3/4

Molecular Partners CEO'su Patrick Amstutz, Jan2004 tarihinde atandı, in görev süresi 22.5 yıldır. in toplam yıllık tazminatı CHF 1.05M olup, şirket hissesi ve opsiyonları dahil olmak üzere 37% maaş ve 63% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.03% ine doğrudan sahiptir ve bu hisseler CHF 2.45M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 5.3 yıldır.

Anahtar bilgiler

Patrick Amstutz

İcra Kurulu Başkanı

CHF 1.1m

Toplam tazminat

CEO maaş yüzdesi	37.05%
CEO görev süresi	22.5yrs
CEO sahipliği	2.0%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Mar 13

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Sep 10

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Apr 11

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Key Insights Molecular Partners to hold its Annual General Meeting on 17th of April Salary of CHF385.0k is part of CEO...

Analiz Makalesi • Jan 09

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Sep 08

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jun 23

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

The latest analyst coverage could presage a bad day for Molecular Partners AG ( VTX:MOLN ), with the analysts making...

Analiz Makalesi • Aug 31

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

One thing we could say about the analysts on Molecular Partners AG ( VTX:MOLN ) - they aren't optimistic, having just...

Analiz Makalesi • May 09

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO Tazminat Analizi

Patrick Amstutz'un ücretlendirmesi Molecular Partners'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-CHF 58m
Dec 31 2025	CHF 1m	CHF 389k	-CHF 62m
Sep 30 2025	n/a	n/a	-CHF 60m
Jun 30 2025	n/a	n/a	-CHF 65m
Mar 31 2025	n/a	n/a	-CHF 59m
Dec 31 2024	CHF 1m	CHF 385k	-CHF 54m
Sep 30 2024	n/a	n/a	-CHF 63m
Jun 30 2024	n/a	n/a	-CHF 58m
Mar 31 2024	n/a	n/a	-CHF 59m
Dec 31 2023	CHF 1m	CHF 385k	-CHF 62m
Sep 30 2023	n/a	n/a	-CHF 60m
Jun 30 2023	n/a	n/a	-CHF 62m
Mar 31 2023	n/a	n/a	-CHF 50m
Dec 31 2022	CHF 1m	CHF 383k	CHF 118m
Sep 30 2022	n/a	n/a	CHF 117m
Jun 30 2022	n/a	n/a	CHF 118m
Mar 31 2022	n/a	n/a	CHF 106m
Dec 31 2021	CHF 1m	CHF 380k	-CHF 64m
Sep 30 2021	n/a	n/a	-CHF 67m
Jun 30 2021	n/a	n/a	-CHF 72m
Mar 31 2021	n/a	n/a	-CHF 66m
Dec 31 2020	CHF 1m	CHF 380k	-CHF 63m
Sep 30 2020	n/a	n/a	-CHF 53m
Jun 30 2020	n/a	n/a	-CHF 48m
Mar 31 2020	n/a	n/a	-CHF 43m
Dec 31 2019	CHF 930k	CHF 363k	-CHF 36m

Tazminat ve Piyasa: Patrick 'nin toplam tazminatı ($USD 1.30M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 891.29K ).

Tazminat ve Kazançlar: Patrick 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Patrick Amstutz (51 yo)

22.5yrs

Görev süresi

CHF 1,050,000

Tazminat

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Amstutz	Co-Founder	22.5yrs	CHF 1.05m	2.03% CHF 2.5m
Michael Stumpp	Co-Founder	22.5yrs	Veri yok	1.93% CHF 2.3m
Robert Hendriks	Senior VP of Finance & Member of Management Board	7yrs	Veri yok	Veri yok
Alexander Zurcher	COO & Member of Management Board	4yrs	Veri yok	0.060% CHF 72.9k
Renate Gloggner	Executive VP of People & Community and Member of Management Board	4.6yrs	Veri yok	0.091% CHF 109.9k
Philippe Legenne	Chief Medical Officer & Member of the Management Board	1.5yrs	Veri yok	0.11% CHF 133.4k
Martin Steegmaier	Chief Scientific Officer & Member of the Management Board	less than a year	Veri yok	Veri yok
Michael Pitzner	Executive VP of Partnering & General Counsel	3.7yrs	Veri yok	Veri yok
Pamela Trail	Strategic Consultant	7yrs	Veri yok	Veri yok
Daniel Steiner	Senior Vice President of Targeted Radio Therapeutics	less than a year	Veri yok	Veri yok
Seth Lewis	Executive Vice President of Corporate Finance	less than a year	Veri yok	Veri yok
Laura Jeanbart	Head of Portfolio Management & Corporate Communications	1.5yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: MOLN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Amstutz	Co-Founder	8.8yrs	CHF 1.05m	2.03% CHF 2.5m
William Burns	Independent Chairman of the Board	8.8yrs	CHF 295.00k	0.11% CHF 132.2k
Vito Palombella	Independent Director	6.3yrs	CHF 128.00k	0.024% CHF 29.2k
Agnete Fredriksen	Independent Director	5.3yrs	CHF 138.00k	0.015% CHF 17.9k
Michael Vasconcelles	Independent Director	6.3yrs	CHF 138.00k	0.024% CHF 29.2k
Sandip Kapadia	Independent Director	6.3yrs	CHF 133.00k	0.024% CHF 29.2k
Jason Lewis	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Clare Fisher	Director	less than a year	Veri yok	Veri yok
Ken Herrmann	Chairman of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Dominik Hochli	Independent Director	5.3yrs	CHF 138.00k	0.013% CHF 16.1k
James Cook	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Michael Morris	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MOLN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/07 13:42
Gün Sonu Hisse Fiyatı	2026/07/07 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Molecular Partners AG 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Robert Burns	H.C. Wainwright & Co.
Richard Vosser	J.P. Morgan
Wei Chang	Leerink Partners LLC

Molecular Partners Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Molecular Partners AG Announces Board and Committee Appointments

Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election

Molecular Partners AG, Annual General Meeting, Apr 14, 2026

Molecular Partners AG Announces Formation of Scientific Advisory Board for Radiopharmaceuticals

Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025

Recent updates

Molecular Partners Provides Update on Clinical Progress Across Pipeline of Darpin Radiotherapeutics

Molecular Partners Advances DARPin Radiotherapeutics With Key Trials and First Data Approaching

Molecular Partners And Orano Med Dose First Patients In Phase 1/2a Trial Of DLL3 Radio-DARPin MP0712

High number of new directors

Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners AG Announces Board and Committee Appointments

Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election

Molecular Partners AG, Annual General Meeting, Apr 14, 2026

Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple Isotopes

New major risk - Share price stability

Molecular Partners AG to Report First Half, 2026 Results on Aug 25, 2026

Price target increased by 12% to CHF10.33

Molecular Partners AG Announces Formation of Scientific Advisory Board for Radiopharmaceuticals

Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025

First half 2025 earnings released: CHF1.02 loss per share (vs CHF0.80 loss in 1H 2024)

New major risk - Revenue size

Molecular Partners AG to Report Fiscal Year 2025 Results on Mar 12, 2026

Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025

Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025

New major risk - Share price stability

Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025

First quarter 2025 earnings released: CHF0.45 loss per share (vs CHF0.34 loss in 1Q 2024)

Molecular Partners AG Presents New Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025

Molecular Partners AG, Annual General Meeting, Apr 16, 2025

Price target increased by 12% to CHF10.50

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Price target increased by 7.2% to CHF10.03

Full year 2024 earnings released: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023)

Molecular Partners AG to Report First Half, 2025 Results on Aug 25, 2025

Consensus revenue estimates fall by 33%

Molecular Partners AG to Report Q4, 2024 Results on Mar 07, 2025

Consensus EPS estimates upgraded to CHF1.53 loss

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023)

New minor risk - Shareholder dilution

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Consensus revenue estimates decrease by 62%, EPS upgraded

Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023)

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023)

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Consensus revenue estimates fall by 45%

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Consensus revenue estimates fall by 29%

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

New major risk - Share price stability

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Consensus revenue estimates decrease by 40%

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

Molecular Partners AG Announces Executive Changes

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Consensus revenue estimates fall by 12%

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Consensus revenue estimates decrease by 73%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations